HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.
Fernanda Faião-FloresMichael F EmmonsMichael A DuranteFumi KinoseBiswarup SahaBin FangJohn M KoomenSrikumar P ChellappanSilvya Stuchi Maria-EnglerUwe RixJonathan D LichtJ William HarbourKeiran S M SmalleyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Together, our studies have identified GPCR-mediated YAP activation and RTK-driven AKT signaling as key pathways involved in the escape of uveal melanoma cells from MEK inhibition. We further demonstrate that HDAC inhibition is a promising combination partner for MEK inhibitors in advanced uveal melanoma.